Mycenax Biotech (ROCO:4726) Cyclically Adjusted Book per Share: NT$12.93 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4726 Mycenax Biotech Inc ROCO:4726
43 GF Score
Price NT$24.50
GF Value NT$47.88
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mycenax Biotech Cyclically Adjusted Book per Share?

Mycenax Biotech ROCO:4726 -4.67% 43 Cyclically Adjusted Book per Share is NT$12.93 as of Dec. 2025. GuruFocus rates ROCO:4726 with a GF Score™ of 43/100 and a GF Value™ of NT$47.88 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Mycenax Biotech's adjusted book value per share for the three months ended in Dec. 2025 was NT$7.716. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$12.93 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Mycenax Biotech's average Cyclically Adjusted Book Growth Rate was -4.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -2.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Mycenax Biotech was 9.00% per year. The lowest was -2.10% per year. And the median was 2.80% per year.

As of today (2026-07-18), Mycenax Biotech's current stock price is NT$24.50. Mycenax Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$12.93. Mycenax Biotech's Cyclically Adjusted PB Ratio of today is 1.89.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Mycenax Biotech was 4.35. The lowest was 1.86. And the median was 2.87.


Mycenax Biotech  (ROCO:4726) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Mycenax Biotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=24.50/12.93
=1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Mycenax Biotech was 4.35. The lowest was 1.86. And the median was 2.87.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Mycenax Biotech Cyclically Adjusted Book per Share Related Terms


Mycenax Biotech Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Mycenax Biotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mycenax Biotech Cyclically Adjusted Book per Share Chart

Mycenax Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.53 13.78 14.13 13.60 12.93

Mycenax Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.60 13.52 13.39 13.22 12.93

ROCO:4726 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Mycenax Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mycenax Biotech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mycenax Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Mycenax Biotech's Cyclically Adjusted PB Ratio falls into.


ROCO:4726
43GF Score
Mycenax Biotech Inc ROCO:4726
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mycenax Biotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mycenax Biotech's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=7.716/324.0540*324.0540
=7.716

Current CPI (Dec. 2025) = 324.0540.

Mycenax Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201603 12.504 238.132 17.016
201606 12.082 241.018 16.245
201609 12.149 241.428 16.307
201612 11.751 241.432 15.772
201703 11.377 243.801 15.122
201706 11.211 244.955 14.831
201709 11.427 246.819 15.003
201712 10.407 246.524 13.680
201803 10.065 249.554 13.070
201806 9.529 251.989 12.254
201809 9.158 252.439 11.756
201812 8.249 251.233 10.640
201903 9.686 254.202 12.348
201906 9.777 256.143 12.369
201909 8.894 256.759 11.225
201912 10.022 256.974 12.638
202003 8.163 258.115 10.248
202006 9.660 257.797 12.143
202009 9.642 260.280 12.004
202012 9.449 260.474 11.755
202103 13.703 264.877 16.764
202106 13.248 271.696 15.801
202109 12.704 274.310 15.008
202112 12.435 278.802 14.453
202203 12.626 287.504 14.231
202206 11.842 296.311 12.951
202209 12.379 296.808 13.515
202212 15.127 296.797 16.516
202303 13.980 301.836 15.009
202306 13.222 305.109 14.043
202309 12.634 307.789 13.302
202312 11.898 306.746 12.569
202403 11.276 312.332 11.699
202406 10.825 314.175 11.165
202409 10.148 315.301 10.430
202412 9.775 315.605 10.037
202503 9.162 319.799 9.284
202506 8.531 322.561 8.570
202509 7.927 324.800 7.909
202512 7.716 324.054 7.716

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$12.93 mean?
Mycenax Biotech (ROCO:4726) has a Cyclically Adjusted Book per Share of NT$12.93 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Mycenax Biotech and its competitors.
Is Mycenax Biotech's Cyclically Adjusted Book per Share too high?
Mycenax Biotech's current Cyclically Adjusted Book per Share is NT$12.93. Overall, Mycenax Biotech has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mycenax Biotech's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Mycenax Biotech's Cyclically Adjusted Book per Share of NT$12.93 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Mycenax Biotech and its competitors. Mycenax Biotech's current Cyclically Adjusted Book per Share is NT$12.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mycenax Biotech stock overvalued right now?
Based on GuruFocus' analysis, Mycenax Biotech (ROCO:4726) is currently considered Possible Value Trap. The stock's GF Value™ is NT$47.88, compared to a current price of NT$24.50 — trading 48.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$12.93. Mycenax Biotech's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Mycenax Biotech (ROCO:4726), the current Cyclically Adjusted Book per Share is NT$12.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mycenax Biotech (ROCO:4726) Overvalued in 2026?

Based on GuruFocus' analysis, Mycenax Biotech stock appears to be undervalued. The current stock price of NT$24.50 is trading 48.8% below its estimated GF Value™ of NT$47.88. GuruFocus considers Mycenax Biotech to be Possible Value Trap.

Key valuation signals for ROCO:4726:

  • Cyclically Adjusted Book per Share: NT$12.93
  • GF Value™: NT$47.88 vs. price of NT$24.50 (48.8% below fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4726 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mycenax Biotech Business Description

Address No. 66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.
43GF Score

Get the complete analysis for ROCO:4726

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.50
Price
NT$47.88
GF Value